ZENTRALINSTITUT FÜR SEELISCHE GESUNDHEIT (CIMH)

Mannheim, Germany

Website

Team Leader

Prof. Tobias Banaschewski

Principal Investigator - Clinical studies
Send message

Dr. Alexander Häge

Send message

Team Staff

Ruth Berg

Study Coordniator
Send message

Dr. Larissa Niemeyer

Investigator
Send message

Dr. Manuel Schlipf

Investigator
Send message

Dr. Konstantin Mechler

Investigator
Send message

Marie Mitschke

PhD Student
Send message

Institute Presentation

The Central Institute of Mental Health (CIMH) in Mannheim, Germany is a globally recognized center of mental health and neuroscience delivering outstanding science, research, and teaching in partnership with institutions at home and abroad. The CAP Department, headed by Prof. Tobias Banaschewski, at the CIMH is specialized in top-level psychiatric treatment and research in neuropsychiatric disorders (e.g., ADHD, Conduct Disorders, Tourette Syndrome, Autism). Research on efficacy and safety of treatment for psychiatric disorders in youths is one of the main focuses of the department’s research agenda. The CAP is equipped with 52 inpatient beds distributed in 4 units/wards plus a day unit for children and an outpatient facility. The department’s outpatient clinic has about 400 new child and adolescent ADHD patients per year. Moreover, the CAP has two units for adolescents: one in collaboration with the department of psychosomatic medicine for adolescents with emotional dysregulation and one in collaboration with the department of psychiatry and psychotherapy for adolescents with schizophrenia. The clinical and research teams include a total of 18 child and adolescent psychiatrists, and 12 senior psychologists, 5 post-docs. CAP CIMH has been involved in several international collaborations including various multisite treatment trials. Prof. Banaschewski and Dr. Häge have been principal investigators in several research projects. The CAP CIMH also has solid experience in the management (WP leadership, country coordinator responsibilities) and implementation of earlier EU FP projects. e.g., the IMAGEN, PERS, STOP, ADDUCE, TACTICS, MATRICS, AGGRESSOTYPE projects and the Innovative Medicines Initiative EU-funded EU-AIMS project and participates in an ongoing multicenter neurofeedback RCT. In this Project, CIMH will mainly be involved in the clinical study where they will take the leading role of one of the clinical trials.